Currently, the predictive biomarkers for immunotherapy mainly include programmed death-ligand 1 (PD-L1), microsatellite instability/defective mismatch repair (MSI/dMMR), and tumour mutational load (TMB) but often ignore the hypoxic tumour microenvironment as a prerequisite (17). This evidence concerns the gene CD274 and neoplasm.